Patents Assigned to Innate Pharma
-
Patent number: 12594343Abstract: The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells. In one embodiment, the present invention provides conjugates of an anti-Nectin-4 antibody to a camptothecin analogue, such as exatecan or SN-38, through a cleavable linker.Type: GrantFiled: January 28, 2021Date of Patent: April 7, 2026Assignee: INNATE PHARMAInventor: Manel Kraiem
-
Patent number: 12528876Abstract: The present invention relates to antibodies, and fragments thereof, that bind and inhibit CD73. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.Type: GrantFiled: October 22, 2021Date of Patent: January 20, 2026Assignee: INNATE PHARMAInventors: Laurent Gauthier, Carine Paturel, Ivan Perrot
-
Patent number: 12448442Abstract: The present invention relates to methods for the treatment of T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and/or oxaliplatin. The treatments are particularly useful in the treatment of peripheral T cell lymphomas, for example PTCL-NOS.Type: GrantFiled: July 21, 2021Date of Patent: October 21, 2025Assignee: INNATE PHARMAInventors: Hatem Abdelazim, Carine Paturel
-
Patent number: 12365731Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.Type: GrantFiled: June 29, 2022Date of Patent: July 22, 2025Assignee: INNATE PHARMAInventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
-
Patent number: 12252543Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.Type: GrantFiled: October 29, 2018Date of Patent: March 18, 2025Assignee: INNATE PHARMAInventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
-
Patent number: 12227569Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.Type: GrantFiled: July 15, 2021Date of Patent: February 18, 2025Assignee: INNATE PHARMAInventors: Laurent Gauthier, Nicolas Schneider
-
Patent number: 12209126Abstract: The present invention relates to the use of NKG2A-neutralizing agents and PD-1 neutralizing agents to treat cancers, notable cancers that are not characterized by DNA mismatch repair deficiency. Provided are methods of treatment of a cancer, as well as compositions and kits useful for treating a cancer that is not characterized by DNA mismatch repair deficiency.Type: GrantFiled: May 14, 2019Date of Patent: January 28, 2025Assignees: MEDIMMUNE LIMITED, INNATE PHARMAInventors: Shaad Essa Abdullah, Ashok Kumar Gupta, Xuyang Song
-
Patent number: 12202907Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.Type: GrantFiled: June 30, 2022Date of Patent: January 21, 2025Assignees: Innate Pharma, Orega BiotechInventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
-
Patent number: 12084498Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.Type: GrantFiled: July 29, 2021Date of Patent: September 10, 2024Assignee: INNATE PHARMAInventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet
-
Patent number: 12037392Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.Type: GrantFiled: April 8, 2021Date of Patent: July 16, 2024Assignee: INNATE PHARMAInventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
-
Patent number: 11999784Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.Type: GrantFiled: June 25, 2019Date of Patent: June 4, 2024Assignee: INNATE PHARMAInventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
-
Patent number: 11970535Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.Type: GrantFiled: December 8, 2020Date of Patent: April 30, 2024Assignee: INNATE PHARMAInventors: Carine Paturel, Helene Sicard
-
Patent number: 11958907Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.Type: GrantFiled: September 2, 2020Date of Patent: April 16, 2024Assignee: INNATE PHARMAInventors: Ivan Perrot, Carine Paturel, Laurent Gauthier
-
Patent number: 11891444Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.Type: GrantFiled: May 10, 2021Date of Patent: February 6, 2024Assignee: INNATE PHARMAInventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
-
Patent number: 11858990Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.Type: GrantFiled: February 28, 2020Date of Patent: January 2, 2024Assignee: INNATE PHARMAInventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
-
Patent number: 11845795Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.Type: GrantFiled: November 8, 2019Date of Patent: December 19, 2023Assignee: INNATE PHARMAInventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
-
Patent number: 11795222Abstract: This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.Type: GrantFiled: March 12, 2019Date of Patent: October 24, 2023Assignee: INNATE PHARMAInventors: Agnes Boyer-Chammard, Pierre Dodion, Roger Cohen
-
Patent number: 11623954Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.Type: GrantFiled: July 9, 2018Date of Patent: April 11, 2023Assignee: INNATE PHARMAInventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
-
Patent number: 11578136Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.Type: GrantFiled: March 16, 2018Date of Patent: February 14, 2023Assignees: INNATE PHARMA, OREGA BIOTECHInventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
-
Patent number: 11572410Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.Type: GrantFiled: July 9, 2020Date of Patent: February 7, 2023Assignee: INNATE PHARMAInventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
